Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Pipeline Review, H2 2016 - 14 Companies & 27 Molecules - Research and Markets

Research and Markets
Posted on: 28 Sep 16

Research and Markets has announced the addition of the "Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016" report to their offering.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 27 molecules. Out of which approximately 25 molecules are developed by Companies and remaining by the Universities/Institutes.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Bromodomain Containing Protein 4 Overview
  3. Therapeutics Development
  4. Pipeline Products for Bromodomain Containing Protein 4 - Overview
  5. Pipeline Products for Bromodomain Containing Protein 4 - Comparative Analysis
  6. Bromodomain Containing Protein 4 - Therapeutics under Development by Companies
  7. Bromodomain Containing Protein 4 - Therapeutics under Investigation by Universities/Institutes
  8. Bromodomain Containing Protein 4 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Bromodomain Containing Protein 4 - Products under Development by Companies
  13. Bromodomain Containing Protein 4 - Products under Investigation by Universities/Institutes
  14. Bromodomain Containing Protein 4 - Companies Involved in Therapeutics Development
  • Aptose Biosciences Inc.
  • Arvinas, Inc.
  • C4 Therapeutics, Inc.
  • Constellation Pharmaceuticals, Inc.
  • ConverGene, LLC
  • Daiichi Sankyo Company, Limited
  • Dybly AG
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Kainos Medicine, Inc.
  • Merck & Co., Inc.
  • Resverlogix Corp.
  • Trillium Therapeutics Inc.
  • Zenith Epigenetics Corp

For more information about this report visit http://www.researchandmarkets.com/research/ftk6ps/bromodomain

View source version on businesswire.com: http://www.businesswire.com/news/home/20160928005736/en/

Business Wire
www.businesswire.com

Last updated on: 28/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.